home / stock / cvac / cvac quote
Last: | $3.34 |
---|---|
Change Percent: | -0.6% |
Open: | $3.35 |
Close: | $3.34 |
High: | $3.46 |
Low: | $3.28 |
Volume: | 670,907 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.34 | $3.35 | $3.34 | $3.46 | $3.28 | 670,907 | 07-02-2024 |
$3.33 | $3.4 | $3.33 | $3.5687 | $3.33 | 708,328 | 07-01-2024 |
$3.4 | $3.36 | $3.4 | $3.42 | $3.28 | 441,469 | 06-28-2024 |
$3.36 | $3.34 | $3.36 | $3.4 | $3.23 | 502,032 | 06-27-2024 |
$3.365 | $3.53 | $3.365 | $3.65 | $3.16 | 1,144,940 | 06-26-2024 |
$3.54 | $3.5 | $3.54 | $3.6875 | $3.4 | 828,865 | 06-25-2024 |
$3.47 | $3.29 | $3.47 | $3.56 | $3.26 | 904,093 | 06-24-2024 |
$3.26 | $3.28 | $3.26 | $3.35 | $3.195 | 546,609 | 06-21-2024 |
$3.26 | $3.38 | $3.26 | $3.388 | $3.18 | 616,163 | 06-20-2024 |
$3.25 | $3.47 | $3.25 | $3.5091 | $3.13 | 1,191,387 | 06-19-2024 |
$3.25 | $3.47 | $3.25 | $3.5091 | $3.13 | 1,191,387 | 06-18-2024 |
$3.48 | $3.6 | $3.48 | $3.63 | $3.43 | 763,288 | 06-17-2024 |
$3.67 | $3.85 | $3.67 | $3.85 | $3.58 | 1,174,371 | 06-14-2024 |
$4 | $4.1 | $4 | $4.15 | $3.925 | 806,615 | 06-13-2024 |
$4.15 | $4.3 | $4.15 | $4.58 | $4.1201 | 730,337 | 06-12-2024 |
$4.25 | $4.5 | $4.25 | $4.5 | $4.01 | 1,384,811 | 06-11-2024 |
$4.59 | $4.46 | $4.59 | $4.595 | $4.27 | 992,798 | 06-10-2024 |
$4.49 | $4.84 | $4.49 | $4.9 | $4.465 | 1,734,608 | 06-07-2024 |
$4.99 | $4.98 | $4.99 | $5.28 | $4.63 | 3,875,277 | 06-06-2024 |
$4.53 | $4.19 | $4.53 | $4.57 | $4.13 | 2,020,818 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine ca...
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK Settlement wi...
CureVac N.V. (NASDAQ: CVAC) is one of today's top gainers. The company's shares have moved 23.1% on the day to $4.05. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing pr...